Serious vascular events in patients with diabetes can be prevented with aspirin use, according to results of the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial, which were presented at the ongoing ESC Congress in Munich, Germany.
Surabhi Dangi-Garimella, PhD
Advertisement
Articles by Surabhi Dangi-Garimella, PhD
Serious vascular events in patients with diabetes can be prevented with aspirin use, according to results of the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial, which were presented at the ESC Congress in Munich, Germany.
Annual meeting explores how to overcome the challenges with patient care that community oncology practices face on a daily basis.
A new study found financial integration between physicians and hospitals has led to higher spending in outpatient care.
Advertisement
Latest Updated Articles
Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential BiomarkersPublished: June 12th 2025 | Updated: June 16th 2025
Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting MembersPublished: June 10th 2025 | Updated: June 12th 2025
NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular CarePublished: June 2nd 2025 | Updated: June 11th 2025
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment LandscapePublished: June 3rd 2025 | Updated: June 11th 2025
Emerging Data: Impacts of ROCKstar and AGAVE-201Published: May 30th 2025 | Updated: June 5th 2025
Measles Cases Climb to 800 in United States as Outbreak Spreads Across BordersPublished: April 18th 2025 | Updated: April 21st 2025
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
3
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5
